| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.4 |